Clinical trials: Spondyloarthritis
Crohn's Disease, Ankylosing Spondylitis
Post Marketing Surveillance of Remicade
The purpose of this study is to understand the safety and effectiveness of infliximab when used in clinical practice. This is a post-marketing surveillance study.
- Trial name
- NCT00724529
- Testing
- Infliximab
- Volunteers
- 938 people
- Sponsor
- Janssen Korea, Ltd., Korea
Rheumatoid Arthritis, Psoriatic Arthritis
A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.
The purpose of this non-interventional study is to evaluate the efficacy of etanercept during routine clinical use over a maximum of 12 months in patients with rheumatoid arthritis (RA), psoriatic arthritis(PsA), axial…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Plaque Psoriasis
- Trial name
- ADEQUATE (NCT02486302)
- Testing
- Etanercept
- Where
- 180 sites in Germany
- Volunteers
- 1,534 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)
This study is the trial to demonstrate how our product is similar to remicade by comparing the results of blood samples in active Ankylosing Spondylitis patients.
- Trial name
- NCT01220518
- Testing
- Infliximab
- Where
- South Korea
- Volunteers
- 257 people
- Sponsor
- Celltrion
Ankylosing Spondylitis
Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis
BCD-055-2 is international multi-center comparative double-blind randomized clinical trial to evaluate efficacy and safety of BCD-055 (JSC "BIOCAD", Russia) and Remicade® in patients with ankylosing spondylitis.
- Trial name
- NCT02762812
- Testing
- BCD-055, Remicade®
- Where
- Russia
- Volunteers
- 199 people
- Sponsor
- Biocad
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis
The primary objective of this study is to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographical Axial Spondyloarthritis
- Trial name
- MANTA-RAy (NCT03926195)
- Testing
- Filgotinib, Standard of Care
- Where
- 71 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 109 people
- Sponsor
- Lakefront Biotherapeutics NV
Psoriatic Arthritis, Axial Spondyloarthritis
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
- Trial name
- NCT07290036
- Testing
- Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc
- Where
- 63 sites in United States, Bulgaria and 4 more
- Volunteers
- 392 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis, Psoriatic Arthritis
A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis
The study is a Worldwide Survey on the Understanding of Psoriatic Disease among Patients with Psoriasis and Psoriatic Arthritis.
- Trial name
- NCT04614831
- Where
- Switzerland
- Volunteers
- 4,978 people
- Sponsor
- Novartis Pharmaceuticals
Spondylitis, Ankylosing
A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED)
The objective of this study is to prove reasonability of registration in Russian federation this new indication (ankylosing spondylitis [AS]) through evaluation of safety and efficacy rate of Remicade 5mg/kg, given as an…
- Trial name
- NCT00779012
- Testing
- Infliximab
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Arthritis, Psoriatic
Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis
The is a double-blind, placebo-controlled, randomized, and multicenter study consisting of a first treatment (FT) period followed by either an observation (OB) period and a re-treatment (RT) period or an open-label (OL) treatment…
- Trial name
- NCT00090129
- Testing
- Onercept
- Where
- 40 sites in United States, Canada
- Volunteers
- 854 people
- Sponsor
- EMD Serono
Psoriatic Arthritis
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
This study will assess the efficacy and safety of secukinumab in patients with active psoriatic arthritis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
- Trial name
- FUTURE 1 (NCT01392326)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 110 sites in United States, Argentina and 17 more
- Volunteers
- 606 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Colitis, Ulcerative
Tracking Biologics Along the Silk Road
The objective of this study is to explore and describe the disease characteristics, treatment and outcomes of participants with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's Disease or ulcerative…
- Trial name
- HARIR (NCT03006198)
- Where
- 8 sites in Algeria, Egypt and 3 more
- Volunteers
- 140 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Anklyosing Spondylitis
16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
This study assessed the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who were tolerant to or had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor
- Trial name
- MEASURE2 (NCT01649375)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 53 sites in United States, Austria and 11 more
- Volunteers
- 219 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Rheumatoid, Arthritis, Psoriatic
A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)
This is a study to assess the use of golimumab (Simponi®) in participants with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
- Conditions
- Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondylitis, Ankylosing
- Trial name
- GO-NICE (NCT01313858)
- Testing
- Simponi®, Methotrexate
- Volunteers
- 1,613 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis, Osteoarthritis
PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity
To prove that the efficacy and safety of Mucosta® (Rebamipide) is non-inferior to those of Cytotec® (Misoprostol), in terms of prevention of NSAID-induced gastric ulcer.
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis
- Trial name
- PRESENT (NCT00576706)
- Testing
- Rebamipide, Misoprostol
- Where
- 10 sites in South Korea
- Volunteers
- 396 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Psoriatic Arthritis
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.
- Trial name
- OPAL BEYOND (NCT01882439)
- Testing
- Tofacitinib
- Where
- 125 sites in United States, Australia and 12 more
- Volunteers
- 395 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis
This is a phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AK111 in subjects with active ankylosing spondylitis.
- Trial name
- NCT05467995
- Testing
- AK111
- Where
- 15 sites in China
- Volunteers
- 125 people
- Sponsor
- Akeso
Spondylitis, Ankylosing
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs
This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with ankylosing spondylitis (AS) who have failed treatment with non-steroidal…
- Trial name
- NCT01209702
- Testing
- tocilizumab
- Where
- 139 sites in United States, Australia and 16 more
- Volunteers
- 306 people
- Sponsor
- Hoffmann-La Roche
Psoriatic Arthritis
A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical study, consisting of a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and an 8-week…
- Trial name
- NCT06640257
- Testing
- SHR-1314 injection
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Ankylosing Spondylitis
Study Evaluating Etanercept Treatment of Patients With Ankylosing Spondylitis
The primary objective of the study was to compare the efficacy of etanercept (25 mg, twice weekly) with that of placebo based on the percentage of patients who achieve the Assessment in Ankylosing Spondylitis (ASAS) response…
- Trial name
- NCT00421915
- Testing
- Enbrel (etanercept)
- Volunteers
- 84 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Non-radiographic Axial Spondyloarthritis
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
This study will establish whether prolonged chronic dosing with secukinumab is needed in participants with Non-radiographic axial spondyloarthritis, (nr-axSpA) who have achieved remission.
- Trial name
- NCT05622708
- Testing
- Secukinumab
- Where
- 61 sites in Belgium, Brazil and 16 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals